Word

IMAGINE WHERE WE CAN GO

Status

Registered

Status Code

700

Status Date

Tuesday, March 6, 2018

Serial Number

86622937

Registration Number

5418590

Registration Date

Tuesday, March 6, 2018

Mark Type

4000

Filing Date

Thursday, May 7, 2015

Published for Opposition

Tuesday, March 22, 2016

Trademark Owner History

BTG International Limited - Original Registrant

Classifications

41 Education, namely, developing, arranging and conducting educational seminars, workshops and programs and providing courses of instruction in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, medical diseases, disorders and related treatments; provision of educational content, namely, providing on-line instruction in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, medical diseases, disorders and related treatments; providing computer, electronic and online databases featuring information about medical education in the field of healthcare, medicine, medical treatment and patient care; training in the use and operation of pharmaceutical products, pharmaceutical preparations, radiopharmaceutical preparations, medical devices, medical imaging apparatus and medical research apparatus and consultation relating thereto; educational services, namely, conducting live and online seminars, classes, workshops, lectures, panel discussions, and training programs in the fields of healthcare, the use of pharmaceutical and medical devices, medical research, surgery, medical science, medicine and medical diseases, disorders and related treatments; Educational services, namely, providing non-downloadable webinars in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, medical diseases, disorders and related treatments; educational services, namely, conducting live and online seminars, classes, workshops, lectures, panel discussions and training in the field of health; educational services, namely, providing non-downloadable webinars in the field of health; education services, namely, conducting online and telephonic instruction and courses in the fields of health and medical issues

5 Pharmaceutical, medicinal preparations and substances, namely, vaccines, antitoxic sera, pharmaceutical preparations for the treatment of cancer, pharmaceutical preparations and substances for the treatment of thrombosis, embolisms, inflammation, and autoimmune disease; pharmaceutical and medicinal preparations and substances, namely, vaccines and vaccine adjuvants, proteins, peptides, sera containing polyclonal antibodies and fragments thereof and polyclonal antibodies and fragments derived therefrom all for use in treating overdose of toxic substances, and sepsis; drug delivery agents, namely, preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances; preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations and substances for use in the circulatory system; pharmaceutical preparations and substances for embolisation; pharmaceutical preparations and substances for embolisation of tumours and arteriovenous malformations (AVMs); pharmaceutical preparations and substances for use in the circulatory system for the treatment of tumours and AVMs; adjuvants for medicinal purposes, vaccine adjuvants and vaccine preparations containing adjuvant; pharmaceutical preparations for the treatment of digoxin, digitalis and other cardio-active glycoside toxicity; chemical reagents for medical and veterinary therapeutic and diagnostic purposes; chemico-pharmaceutical preparations for use in the treatment of digoxin, digitalis and other cardio-active glycoside toxicity; chemical preparations for medical and pharmaceutical purposes and medicines for use in the treatment of digoxin, digitalis and other cardio-active glycoside toxicity; transarterial chemoembolisation pharmaceutical preparations, vaccines and sera; pharmaceutical preparations in the form of foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams for use in producing foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams and for use in preparing foams, for sclerotherapy, phlebology, angiology and proctology, namely, for the treatment of oesophageal varices, hydroceles, in sterilisation treatment and for treatment of varicose veins, and arterio-venous malformations; pharmaceutical preparations containing methotrexate antidotes; pharmaceutical preparations containing 5-fluorouracil antidotes; pharmaceutical preparations for use in chemotherapy and for the treatment of autoimmune diseases; pharmaceutical preparations used for regulating toxicity levels of therapeutic agents; pharmaceutical preparations used for depleting concentrations of therapeutic agents

44 Provision of medical and surgical information; provision of medical and surgical information on-line from a computer database or from the Internet or by telecommunication means; services for the provision of medical information; providing medical information; providing a website featuring information regarding medicine, medical treatment, patient care, prescription drugs, ordering, prescribing, and dispensing practices of drugs, treatment and aftercare; providing a website featuring medical information regarding medicine, medical treatment, patient care, prescription drugs, ordering, prescribing, and dispensing practices of drugs, treatment and aftercare; medical services, namely, diagnosis, assessment, treatment and aftercare in the fields of sclerotherapy, phlebology, angiology, proctology, interventional oncology, ablation of tumours using embolic beads, ablation of tumours using embolic drug eluting beads, and in connection with varicose veins, arterio-venous malformations; medical analysis for the diagnosis and treatment of persons; pharmacy advice; pharmacy advice, namely, medical advice on pharmaceuticals; advisory services relating to health and healthcare; advisory services relating to medicine and medical treatment and services; medical advisory services relating to patient care; conducting health assessment surveys, health risk assessment surveys, treatment outcome surveys and health advice and information services; health care consultancy services; consultancy services relating to medical treatment; information services relating to health care and medical treatment; providing health and medical information via hotline services enabling medical, counselling, and nursing personnel access to records to enable assistance with patient coverage, reimbursement, ordering, and site-of-care support questions; provision of medical records by hotline services; healthcare consultancy services, namely, providing a hotline for medical, counselling and nursing personnel; healthcare consultancy services, namely, providing patient and patient medical record information by hotline services; providing health and medical information by hotline services; advisory services relating to health and healthcare; advisory services relating to medicine and medical treatment and services; medical advisory services relating to patient care; healthcare consultancy services; consultancy services relating to medical treatment; information services relating to healthcare and medical treatment; advisory services relating to medical apparatus, instruments and preparations; medical advisory services relating to medical apparatus, instruments and preparations; advisory services relating to medical services; preparation of medical reports; advisory, consultancy and information services relating to the aforesaid services

10 Surgical and medical apparatus and instruments, namely, medical syringes, surgical and medical apparatus for producing and administering pharmaceutical foams, surgical and medical apparatus for producing foams for treatment of varicose veins, arterio-venous malformations, oesophageal varices and hydroceles, devices for intravenous administration of pharmaceutical foam, and diagnostic devices for grading the severity of venous conditions, and toxic drugs overdose; surgical, medical and veterinary apparatus and instruments, namely, medical device, apparatus and instruments for treating cancer; drug delivery embolisation apparatus, instruments and systems; apparatus and instruments for use in the circulatory system, namely, catheters, injection syringes and sealed vials; medical apparatus and instruments for embolisation; surgical and medical apparatus and instruments, namely, catheters, injection syringes and sealed vial devices for dispensing microspheres during embolisation procedures in blood vessels and in the circulatory system; embolisation apparatus, instruments and systems comprising surgical and medical instruments for embolization, namely, embolic devices for use in treating cancer and tumors, embolic devices for treating arteriovenous malformations (AVMs) of the body, and embolic devices for use in treating tumors; drug delivery embolisation systems; drug delivery apparatus and instruments, namely, a drug delivery system comprised of injection syringes and sealed vials; injection syringes for use with catheters; apparatus and instruments for use in the circulatory system, namely, catheters, injection syringes and sealed vials for dispensing microspheres during embolisation procedures in blood vessels and in the circulatory system; medical apparatus and instruments for embolization, namely, medical devices in the nature of particles, namely, embolic microspheres for embolization; surgical and medical apparatus and instruments for embolisation, namely, embolisation apparatus, instruments and systems comprising microspheres and injection syringes for use in blood vessels and the circulatory system to carry out embolisation; surgical and medical apparatus for producing and administering foams for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical and medical apparatus for producing and administering sclerosing foams for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical and medical apparatus for producing and administering foams for use in sclerotherapy, phlebology, angiology and proctology; surgical and medical apparatus for use in treatment of varicose veins, arterio-venous malformations, oesophageal varices and hycroceles; medical devices for intravenous administration of sclerosing foam for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; medical devices for monitoring the position and effect of sclerosing foam in the human body for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; medical diagnostic apparatus for diagnosing all the above medical conditions, namely, varicose veins, arterio-venous malformations, oesophageal varices, spider veins hydroceles, cancer, tumors, and circulatory system conditions and pulmonary and thoracic conditions; compression bandages; component parts and fittings for all of the aforesaid goods

Trademark Events

Jul 20, 2023

Teas Change Of Correspondence Received

Jul 20, 2023

Attorney/Dom.Rep.Revoked And/Or Appointed

Jul 20, 2023

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Mar 16, 2023

Applicant/Correspondence Changes (Non-Responsive) Entered

Mar 16, 2023

Teas Change Of Correspondence Received

Mar 16, 2023

Attorney/Dom.Rep.Revoked And/Or Appointed

Mar 16, 2023

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Mar 16, 2023

Teas Change Of Owner Address Received

Mar 6, 2023

Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed

Aug 30, 2021

Applicant/Correspondence Changes (Non-Responsive) Entered

Aug 30, 2021

Teas Change Of Correspondence Received

Aug 30, 2021

Attorney/Dom.Rep.Revoked And/Or Appointed

Aug 30, 2021

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Aug 30, 2021

Teas Change Of Owner Address Received

Aug 29, 2020

Applicant/Correspondence Changes (Non-Responsive) Entered

Aug 29, 2020

Teas Change Of Correspondence Received

Aug 29, 2020

Teas Withdrawal As Domestic Representative Received

Aug 29, 2020

Attorney/Dom.Rep.Revoked And/Or Appointed

Aug 29, 2020

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Aug 29, 2020

Teas Change Of Owner Address Received

Mar 6, 2018

Registered-Principal Register

Feb 20, 2018

Assigned To Examiner

Feb 1, 2018

Notice Of Acceptance Of Statement Of Use E-Mailed

Jan 31, 2018

Allowed Principal Register - Sou Accepted

Jan 30, 2018

Statement Of Use Processing Complete

Nov 16, 2017

Use Amendment Filed

Nov 30, 2017

Case Assigned To Intent To Use Paralegal

Nov 16, 2017

Teas Statement Of Use Received

May 5, 2017

Notice Of Approval Of Extension Request E-Mailed

May 3, 2017

Sou Extension 2 Granted

May 3, 2017

Sou Extension 2 Filed

May 3, 2017

Teas Extension Received

Sep 16, 2016

Notice Of Approval Of Extension Request E-Mailed

Sep 14, 2016

Sou Extension 1 Granted

Sep 14, 2016

Sou Extension 1 Filed

Sep 14, 2016

Teas Extension Received

May 17, 2016

Noa E-Mailed - Sou Required From Applicant

Mar 22, 2016

Official Gazette Publication Confirmation E-Mailed

Mar 22, 2016

Published For Opposition

Mar 2, 2016

Notification Of Notice Of Publication E-Mailed

Feb 12, 2016

Law Office Publication Review Completed

Feb 5, 2016

Approved For Pub - Principal Register

Feb 5, 2016

Examiner's Amendment Entered

Feb 5, 2016

Notification Of Examiners Amendment E-Mailed

Feb 5, 2016

Examiners Amendment E-Mailed

Feb 5, 2016

Examiners Amendment -Written

Feb 4, 2016

Teas/Email Correspondence Entered

Feb 3, 2016

Correspondence Received In Law Office

Feb 3, 2016

Teas Response To Office Action Received

Aug 4, 2015

Notification Of Non-Final Action E-Mailed

Aug 4, 2015

Non-Final Action E-Mailed

Aug 4, 2015

Non-Final Action Written

Jul 28, 2015

Assigned To Examiner

Jul 8, 2015

Preliminary/Voluntary Amendment - Entered

Jul 7, 2015

Assigned To Lie

Jun 30, 2015

Assigned To Lie

Jun 19, 2015

Assigned To Lie

Jun 11, 2015

Teas Voluntary Amendment Received

May 16, 2015

New Application Office Supplied Data Entered

May 11, 2015

New Application Entered